arexvy rsv - Search News

News

GSK, RSV and European Medicines Agency

GSK says EU regulator reviewing expanded use of RSV vaccine

GSK said on Friday the European Medicines Agency had accepted the drugmaker's application to expand the use of its respiratory syncytial virus (RSV) vaccine, Arexvy, to adults aged 18 and above. An expanded approval will help GSK better compete with rivals such as Merck's mRESVIA and Pfizer's Abrysvo after U.

Medical Dialogues · 1d

GSK RSV vaccine Arexvy accepted for regulatory review by EMA to expand use in adults 18 years, older

· 2d

GSK (LSE:GSK) Seeks European Expansion Of RSV Vaccine To Adults 18 And Older

STAT3d

FDA clears Moderna’s RSV vaccine for use in people aged 18 to 59

The FDA expanded the approval of Moderna’s RSV vaccine, extending the license to include more adults and giving the company a ...

Pharmabiz2d

EMA accepts for regulatory review GSK’s RSV vaccine, Arexvy to expand use in adults 18 years and older

EMA accepts for regulatory review GSK’s RSV vaccine, Arexvy to expand use in adults 18 years and older: London, UK Saturday, June 14, 2025, 10:00 Hrs [IST] GSK plc announced tha ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results

News

GSK, RSV and European Medicines Agency

Trending now